

Dean A Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/810321/publications.pdf>

Version: 2024-02-01

191
papers

10,223
citations

36203

51
h-index

40881

93
g-index

202
all docs

202
docs citations

202
times ranked

11795
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebral organoids containing an <i>AUTS2</i> missense variant model microcephaly. <i>Brain</i> , 2023, 146, 387-404.	3.7	11
2	Decrease post-transplant relapse using donor-derived expanded NK-cells. <i>Leukemia</i> , 2022, 36, 155-164.	3.3	43
3	Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. <i>Methods in Cell Biology</i> , 2022, 167, 163-170.	0.5	2
4	Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. <i>Frontiers in Genome Editing</i> , 2022, 4, 781531.	2.7	0
5	The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). <i>Current Treatment Options in Oncology</i> , 2022, 23, 381-403.	1.3	5
6	CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 834002.	1.3	8
7	Role of NK-Like CD8 ⁺ T Cells during Asymptomatic <i>Borrelia burgdorferi</i> Infection. <i>Infection and Immunity</i> , 2022, , e0055521.	1.0	0
8	Evaluation of allogeneic and autologous membrane-bound IL-21 ^{hi} expanded NK cells for chronic lymphocytic leukemia therapy. <i>Blood Advances</i> , 2022, 6, 5641-5654.	2.5	6
9	Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. <i>Cell Reports Methods</i> , 2022, 2, 100236.	1.4	19
10	Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. <i>Stem Cell Research and Therapy</i> , 2021, 12, 211.	2.4	33
11	Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2021, 25, e14041.	0.5	3
12	Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. <i>Frontiers in Veterinary Science</i> , 2021, 8, 672361.	0.9	8
13	Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2 ⁺ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. , 2021, 9, e002267.		14
14	Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 926.e1-926.e10.	0.6	2
15	NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 146.	2.8	67
16	Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. <i>Blood Advances</i> , 2021, 5, 4605-4618.	2.5	10
17	Adoptive immunotherapy with double ⁺ (CD56 ⁺ /CD16 ⁺) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. <i>British Journal of Haematology</i> , 2021, 195, 710-721.	1.2	22
18	A Multi-Omics Approach for Evaluating the Impact of Cytokines and Donor Source on NK Cell Expansion. <i>Blood</i> , 2021, 138, 1769-1769.	0.6	0

#	ARTICLE	IF	CITATIONS
19	The role of AhR in transcriptional regulation of immune cell development and function. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188335.	3.3	49
20	Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. <i>Frontiers in Immunology</i> , 2020, 11, 2196.	2.2	21
21	Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity. <i>Seminars in Hematology</i> , 2020, 57, 201-212.	1.8	17
22	Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma. , 2020, 8, e001238.		11
23	Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. <i>Cytotherapy</i> , 2020, 22, 369-376.	0.3	13
24	Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. <i>Neuro-Oncology</i> , 2020, 22, 1214-1225.	0.6	48
25	Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2020, 22, 1302-1314.	0.6	42
26	CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. <i>Blood</i> , 2020, 136, 2416-2427.	0.6	77
27	Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. <i>PLoS ONE</i> , 2020, 15, e0224775.	1.1	15
28	Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells. <i>Cytotherapy</i> , 2020, 22, 322-328.	0.3	17
29	Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. <i>Blood Advances</i> , 2020, 4, 1350-1356.	2.5	19
30	Natural Killer Cell Immunotherapy for Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1257, 141-154.	0.8	11
31	CD33 Targeting Primary CAR-NK Cells Generated By CRISPR Mediated Gene Insertion Show Enhanced Anti-AML Activity. <i>Blood</i> , 2020, 136, 3-3.	0.6	13
32	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. <i>Oncotarget</i> , 2020, 11, 3035-3047.	0.8	4
33	A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2020, 136, 44-44.	0.6	2
34	Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 11-12.	0.6	1
35	Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-gamma Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449). <i>Blood</i> , 2020, 136, 2-4.	0.6	1
36	Optimizing Ex-Vivo Expanded NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL). <i>Blood</i> , 2020, 136, 23-24.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
38	Tgfi ² -Imprinting Decrease CD38 Expression and Lead to Metabolic Reprogramming on Primary NK Cell. <i>Blood</i> , 2020, 136, 4-4.	0.6	16
39	Expression of carcinoma, apoptosis, and cell death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27783.	0.8	11
40	Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e219-e220.	2.0	1
41	Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. <i>Immunological Reviews</i> , 2019, 290, 85-99.	2.8	81
42	Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. <i>Scientific Reports</i> , 2019, 9, 14916.	1.6	66
43	Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. <i>Stem Cells</i> , 2019, 37, 1481-1491.	1.4	35
44	Immunotherapeutic Challenges for Pediatric Cancers. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 38-48.	2.0	26
45	Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon- γ Production, and Lifespan. <i>International Journal of Molecular Sciences</i> , 2019, 20, 443.	1.8	15
46	Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e221-e222.	2.0	1
47	Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 594-597.e4.	1.5	5
48	Combining ROR1- Specific Chimeric Antigen Receptor (CAR) NK Cells with IL-15 Superagonist (N-803/ALT-803) to Target Chemotherapy Resistant Neuroblastoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S334.	2.0	1
49	Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. <i>Journal of Neuro-Oncology</i> , 2019, 142, 395-407.	1.4	25
50	Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. <i>Frontiers in Immunology</i> , 2019, 10, 2873.	2.2	84
51	Immunotherapies for pediatric cancer: current landscape and future perspectives. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 573-594.	2.7	20
52	Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 346-358.e6.	1.5	59
53	Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. <i>Blood</i> , 2019, 134, 700-700.	0.6	3
54	CD38 Knockout Primary NK Cells to Prevent "Fratricide" and Boost Daratumumab Activity. <i>Blood</i> , 2019, 134, 870-870.	0.6	6

#	ARTICLE	IF	CITATIONS
55	CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers. <i>Blood</i> , 2019, 134, 3597-3597.	0.6	3
56	NKG2D CAR-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells. <i>Blood</i> , 2019, 134, 2667-2667.	0.6	1
57	Improved Bone Marrow Homing of NK Cells through PM21 Particle Stimulated Enhancement of Fucosylation of E-Selectin Ligand. <i>Blood</i> , 2019, 134, 3598-3598.	0.6	0
58	IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL. <i>Blood</i> , 2019, 134, 4302-4302.	0.6	1
59	Aggressive natural killer-cell leukemia—mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	5.8	107
60	Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 575-587.	2.0	36
61	Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. <i>Journal of Immunotherapy</i> , 2018, 41, 64-72.	1.2	29
62	Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 337-342.	2.0	8
63	IMMU-19. LSD1 MODULATES NK CELL IMMUNOTHERAPY THROUGH AN ONCO-IMMUNOGENIC GENE SIGNATURE IN DIPG. <i>Neuro-Oncology</i> , 2018, 20, i102-i102.	0.6	2
64	TGF β 2 Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. <i>Cancers</i> , 2018, 10, 423.	1.7	38
65	Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of senescent NK cells to lose CD57 expression and start expressing NKG2A. <i>PLoS ONE</i> , 2018, 13, e0208469.	1.1	23
66	Protect NIH's DNA advisory committee. <i>Science</i> , 2018, 362, 409-410.	6.0	2
67	Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. <i>Frontiers in Immunology</i> , 2018, 9, 1711.	2.2	24
68	Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. <i>Blood Advances</i> , 2018, 2, 1818-1827.	2.5	11
69	IMMU-22. NATURAL KILLER CELL IMMUNOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, i103-i103.	0.6	1
70	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27313.	0.8	11
71	Expanded CD56 ^{superbright} CD16 ⁺ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. <i>Cancer Immunology Research</i> , 2018, 6, 1174-1185.	1.6	38
72	Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	53

#	ARTICLE	IF	CITATIONS
73	NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells. <i>Blood</i> , 2018, 132, 590-590.	0.6	20
74	Disruption of SOCS3 Promotes the Anti-Cancer Efficacy of Primary NK Cells. <i>Blood</i> , 2018, 132, 5687-5687.	0.6	10
75	Initial results of two phase I trials delivering mbIL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7008-7008.	0.8	3
76	Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8006-8006.	0.8	8
77	Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. <i>PLoS ONE</i> , 2018, 13, e0191358.	1.1	93
78	Outcomes of Pediatric Patients with Acute Leukemia Following Adult Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching. <i>Blood</i> , 2018, 132, 4647-4647.	0.6	0
79	Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies. <i>Blood</i> , 2018, 132, 732-732.	0.6	0
80	Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL). <i>Blood</i> , 2018, 132, 3697-3697.	0.6	0
81	Natural killer cell adoptive immunotherapy: Coming of age. <i>Clinical Immunology</i> , 2017, 177, 3-11.	1.4	40
82	ROR1-Specific Chimeric Antigen Receptor (CAR) NK Cell Immunotherapy for High Risk Neuroblastomas and Sarcomas. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S136-S137.	2.0	13
83	The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3. <i>Scientific Reports</i> , 2017, 7, 45266.	1.6	61
84	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 457-466.	1.2	158
85	Phase 1 clinical trial using mbIL21 ex vivo expanded donor-derived NK cells after haploidentical transplantation. <i>Blood</i> , 2017, 130, 1857-1868.	0.6	256
86	Combined Stimulation with Interleukin-18 and Interleukin-12 Potently Induces Interleukin-8 Production by Natural Killer Cells. <i>Journal of Innate Immunity</i> , 2017, 9, 511-525.	1.8	27
87	Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells. <i>Scientific Reports</i> , 2017, 7, 12083.	1.6	22
88	IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN- γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation. <i>Molecular Immunology</i> , 2017, 88, 138-147.	1.0	84
89	Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells. <i>Stem Cells</i> , 2017, 35, 1065-1079.	1.4	89
90	Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. <i>Leukemia</i> , 2017, 31, 234-237.	3.3	30

#	ARTICLE	IF	CITATIONS
91	Natural killer cells in malignant hematology: A primer for the non-immunologist. <i>Blood Reviews</i> , 2017, 31, 1-10.	2.8	34
92	Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines. <i>Frontiers in Immunology</i> , 2017, 8, 391.	2.2	42
93	Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. <i>Breast Cancer Research</i> , 2017, 19, 76.	2.2	59
94	Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. , 2017, 5, 98.		101
95	Assessment of antitumor function of NK cells expanded with exosomes from K562.mb21 cells.. <i>Journal of Clinical Oncology</i> , 2017, 35, 132-132.	0.8	2
96	Preclinical assessment of PM21-particle expanded natural killer cells for ovarian cancer treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 127-127.	0.8	1
97	NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells. <i>Frontiers in Immunology</i> , 2016, 7, 521.	2.2	39
98	Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. <i>Journal of Immunotherapy</i> , 2016, 39, 205-217.	1.2	29
99	Engineering Receptor Expression on Natural Killer Cells Through Trogocytosis. <i>Methods in Molecular Biology</i> , 2016, 1441, 253-265.	0.4	2
100	Electroporation of siRNA to Silence Gene Expression in Primary NK Cells. <i>Methods in Molecular Biology</i> , 2016, 1441, 267-276.	0.4	7
101	In Vivo 19F-Magnetic Resonance Imaging of Adoptively Transferred NK Cells. <i>Methods in Molecular Biology</i> , 2016, 1441, 317-332.	0.4	18
102	Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment. <i>Cytotherapy</i> , 2016, 18, 653-663.	0.3	68
103	Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21. <i>Methods in Molecular Biology</i> , 2016, 1441, 175-193.	0.4	27
104	Regulatory Considerations for NK Cells Used in Human Immunotherapy Applications. <i>Methods in Molecular Biology</i> , 2016, 1441, 347-361.	0.4	12
105	Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1290-1298.	2.0	113
106	Results of a 2â€arm, phase 2 clinical trial using postâ€transplantation cyclophosphamide for the prevention of graftâ€versusâ€host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	2.0	75
107	Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7788-E7797.	3.3	320
108	Repression of GSK3 restores NK cell cytotoxicity in AML patients. <i>Nature Communications</i> , 2016, 7, 11154.	5.8	86

#	ARTICLE	IF	CITATIONS
109	Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. <i>Molecular Imaging and Biology</i> , 2016, 18, 838-848.	1.3	22
110	Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. <i>Oncolmmunology</i> , 2016, 5, e1115178.	2.1	79
111	Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFN γ secretion. <i>Oncolmmunology</i> , 2016, 5, e1100790.	2.1	46
112	Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients. <i>Bone Marrow Transplantation</i> , 2016, 51, 27-33.	1.3	12
113	Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 3363-3376.	3.9	399
114	Generation of Natural Killer Cell Lymphoma Models In Vitro by Gene Editing. <i>Blood</i> , 2016, 128, 2724-2724.	0.6	4
115	Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. <i>Blood</i> , 2016, 128, 500-500.	0.6	3
116	The off-target effects of nonspecific NK cells. <i>Blood</i> , 2015, 125, 744-745.	0.6	5
117	A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry. <i>PLoS ONE</i> , 2015, 10, e0141074.	1.1	71
118	Trace Evidence: Identifying Natural Cancer Killers After the Crime. <i>EBioMedicine</i> , 2015, 2, 1276-1277.	2.7	0
119	Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1714-1720.	2.0	30
120	Autologous Bone Marrow Mononuclear Cells Reduce Therapeutic Intensity for Severe Traumatic Brain Injury in Children*. <i>Pediatric Critical Care Medicine</i> , 2015, 16, 245-255.	0.2	60
121	Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial. <i>Journal of Neuro-Oncology</i> , 2015, 125, 133-141.	1.4	20
122	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015, 7, 967-980.	1.0	83
123	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. <i>Cancer Research</i> , 2015, 75, 3505-3518.	0.4	327
124	Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. <i>Leukemia</i> , 2015, 29, 788-797.	3.3	18
125	The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells. <i>Pharmaceutical Research</i> , 2015, 32, 779-792.	1.7	86
126	Universal Artificial Antigen Presenting Cells to Selectively Propagate T Cells Expressing Chimeric Antigen Receptor Independent of Specificity. <i>Journal of Immunotherapy</i> , 2014, 37, 204-213.	1.2	26

#	ARTICLE	IF	CITATIONS
127	Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1362-1368.	0.8	29
128	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1975-1981.	2.0	207
129	Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. <i>Pediatric Blood and Cancer</i> , 2014, 61, 618-626.	0.8	35
130	Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10660-10665.	3.3	171
131	Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies. <i>Clinical Cancer Research</i> , 2014, 20, 5708-5719.	3.2	114
132	Is there an expiration date for a cord blood unit in storage?. <i>Bone Marrow Transplantation</i> , 2014, 49, 1109-1112.	1.3	9
133	Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. <i>Blood</i> , 2014, 124, 403-411.	0.6	63
134	Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. <i>Blood</i> , 2014, 124, 3241-3249.	0.6	85
135	Tumor Lysing Genetically Engineered T Cells Loaded with Multi-Modal Imaging Agents. <i>Scientific Reports</i> , 2014, 4, 4502.	1.6	29
136	Natural Killer Cells for Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2014, 804, 341-353.	0.8	28
137	Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. <i>Journal of Molecular Medicine</i> , 2013, 91, 459-472.	1.7	19
138	Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor. <i>Molecular Therapy</i> , 2013, 21, 638-647.	3.7	134
139	Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 231-238.	0.6	58
140	Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. <i>Blood</i> , 2013, 122, 1341-1349.	0.6	243
141	T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. <i>Molecular Therapy</i> , 2013, 21, 629-637.	3.7	200
142	Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. <i>Clinical and Experimental Immunology</i> , 2013, 172, 104-112.	1.1	41
143	Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. <i>Molecular Immunology</i> , 2013, 54, 296-301.	1.0	50
144	Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy. <i>Stem Cells Translational Medicine</i> , 2013, 2, 274-283.	1.6	293

#	ARTICLE	IF	CITATIONS
145	Membrane-bound TRAIL Supplements Natural Killer Cell Cytotoxicity Against Neuroblastoma Cells. <i>Journal of Immunotherapy</i> , 2013, 36, 319-329.	1.2	42
146	Mentoring in Pediatric Oncology. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 456-461.	0.3	20
147	Sleeping Beauty System to Redirect T-cell Specificity for Human Applications. <i>Journal of Immunotherapy</i> , 2013, 36, 112-123.	1.2	74
148	Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy. <i>Clinical Cancer Research</i> , 2013, 19, 2132-2143.	3.2	101
149	The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation. <i>Oncogene</i> , 2013, 32, 1691-1701.	2.6	38
150	Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. <i>PLoS ONE</i> , 2013, 8, e76781.	1.1	155
151	Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials. <i>PLoS ONE</i> , 2013, 8, e57838.	1.1	104
152	Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. <i>Blood</i> , 2013, 122, 2167-2167.	0.6	5
153	<i>Ex Vivo</i> and <i>In Vivo</i> Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD^{33} Acute Myeloid Leukemia. <i>Advances in Hematology</i> , 2012, 2012, 1-10.	0.6	94
154	Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. <i>Scientific Reports</i> , 2012, 2, 249.	1.6	57
155	Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. <i>Blood</i> , 2012, 119, 5164-5172.	0.6	106
156	NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. <i>Immunotherapy</i> , 2012, 4, 305-313.	1.0	23
157	A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. <i>Blood</i> , 2012, 119, 5697-5705.	0.6	437
158	Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies. <i>Human Gene Therapy</i> , 2012, 23, 444-450.	1.4	99
159	Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. <i>PLoS ONE</i> , 2012, 7, e30264.	1.1	488
160	Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells. <i>Journal of Visualized Experiments</i> , 2011, , .	0.2	109
161	Autologous Bone Marrow Mononuclear Cell Therapy for Severe Traumatic Brain Injury in Children. <i>Neurosurgery</i> , 2011, 68, 588-600.	0.6	143
162	The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. <i>Gene Therapy</i> , 2011, 18, 849-856.	2.3	91

#	ARTICLE	IF	CITATIONS
163	Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. <i>Cancer Research</i> , 2011, 71, 3516-3527.	0.4	171
164	A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. <i>Biomedical Microdevices</i> , 2010, 12, 855-863.	1.4	30
165	Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1180-1184.	0.8	5
166	Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. <i>Leukemia</i> , 2010, 24, 1059-1062.	3.3	6
167	Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies. <i>Cancer Research</i> , 2010, 70, 3915-3924.	0.4	40
168	piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies. <i>Human Gene Therapy</i> , 2010, 21, 427-437.	1.4	124
169	IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive Tumors. <i>Journal of Immunology</i> , 2010, 184, 2348-2354.	0.4	67
170	Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. <i>European Journal of Cancer</i> , 2010, 46, 2771-2780.	1.3	15
171	Acquisition, Preparation, and Functional Assessment of Human NK Cells for Adoptive Immunotherapy. <i>Methods in Molecular Biology</i> , 2010, 651, 61-77.	0.4	18
172	Combination of Gene Therapy and Nanoparticle Imaging for Improving T-Cell Therapy.. <i>Blood</i> , 2010, 116, 1479-1479.	0.6	6
173	Large scale generation of genetically modified T-cells using micro-electroporators for cancer treatments. , 2009, , .		0
174	PET imaging of T cells derived from umbilical cord blood. <i>Leukemia</i> , 2009, 23, 620-622.	3.3	13
175	New insights to the MLL recombinome of acute leukemias. <i>Leukemia</i> , 2009, 23, 1490-1499.	3.3	363
176	The Contribution of Signaling Endodomains to CD33-Mediated Killing of Acute Myeloid Leukemia by Natural Killer Cells Transiently Modified with Chimeric Antigen Receptor.. <i>Blood</i> , 2009, 114, 2463-2463.	0.6	0
177	EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH. <i>Pediatric Blood and Cancer</i> , 2008, 50, 728-730.	0.8	3
178	Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. <i>Blood</i> , 2008, 112, 154-154.	0.6	13
179	Differential Expression of VEGF Receptors on Human T Cell Subsets. <i>Blood</i> , 2008, 112, 4906-4906.	0.6	0
180	C/EBP β suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 108-114.	1.0	15

#	ARTICLE	IF	CITATIONS
181	Rotavirus Vaccines. New England Journal of Medicine, 2006, 354, 1747-1751.	13.9	15
182	Leukemia Targeting Via Cytotoxic T Cells Expressing a CD33 Specific Chimeric Receptor.. Blood, 2006, 108, 453-453.	0.6	0
183	Liver transplantation for severe hepatic graft-versus-host disease: An analysis of aggregate survival data. Liver Transplantation, 2005, 11, 525-531.	1.3	40
184	Outcome of Alternative Donor Transplantation for Severe Aplastic Anemia Can Be Comparable to Outcome with Matched Related Donors.. Blood, 2005, 106, 2052-2052.	0.6	0
185	Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders.. Blood, 2005, 106, 2746-2746.	0.6	0
186	Human Bone Marrow Mesenchymal Stem Cells Enhance Extramedullary Engraftment and Proliferation of Human AML Blasts in NOD-SCID Mice.. Blood, 2005, 106, 2312-2312.	0.6	0
187	Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands. Immunity, 2004, 20, 107-118.	6.6	517
188	Granulocytic Sarcoma Presenting as Pneumonia in a Child With t(8;21) Acute Myelogenous Leukemia: Diagnosis by Fluorescent In Situ Hybridization. Journal of Pediatric Hematology/Oncology, 2004, 26, 431-434.	0.3	13
189	Activated peripheral T lymphocytes undergo apoptosis when cultured with monocytes activated by HLA class II ligation. Cellular Immunology, 2003, 225, 101-112.	1.4	6
190	HIV false positivity after hepatitis B vaccination. Lancet, The, 1992, 339, 1060.	6.3	24
191	Optimization and Validation of CAR Transduction into Human Primary NK Cells Using CRISPR and AAV. SSRN Electronic Journal, 0, , .	0.4	1